Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 10/20 | 1.00 |
| ▸ | JAK2 | O60674 | 18/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itacitinib SCHEMBL29377548 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29456952 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL2396080 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29395727 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29395309 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29379939 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL2392474 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL30986034 | 0.94 | JAK2 (0.88) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL2392537 | 0.94 | JAK2 (0.88) | JAK2JAK1MERTKTYK2AXL | |
| SCHEMBL24327904 | 0.93 | JAK2 (0.86) | JAK2JAK1MERTKTYK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2023 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | claimed |
| EP-4149548-B1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260098088-A1 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | DISC MEDICINE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | VIVAVISION BIOTECH LTD (CN) | 2026-03-05 | — | — | US | claimed |
| US-20260060987-A1 | METHODS AND COMPOSITIONS FOR RADIOPROTECTION AND MITIGATION OF RADIATION-INDUCED INJURY USING KINASE INHIBITORS | INCYTE CORP (US) | 2026-03-05 | — | — | US | claimed |
| EP-4702973-A1 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-12559553-B2 | IL-31 modulators for treating FXR-induced pruritus | GILEAD SCIENCES, INC. (US) | 2026-02-24 | — | — | US | claimed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| WO-2022040172-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220056034-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION | 2022-02-24 | — | — | US | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| EP-3941474-A2 | BIOMARKERS FOR VITILIGO | Incyte Corporation (US) | 2022-01-26 | — | — | EP | claimed |